1212 GMT - Roche Holding's confidence in its portfolio of medicines for obesity and diabetes seems to be growing as the Swiss drugmaker seeks an expansion into broader cardiovascular indications, UBS analysts say in a research note. "Management continues to expect a highly segmented obesity market, with orals a critical pillar both as monotherapy and in combinations, and sees oral therapies expanding the market," the analysts say. Roche believes the glucose-control performance of its enicepatide drug candidate in a recent midstage trial warrants a head-to-head comparison study against Eli Lilly's Mounjaro in diabetes, with no decision yet on a similar study in obesity, they add. Moreover, the company plans to test enicepatide for cardiac conditions, while moving two other experimental obesity drugs to late-stage studies. Shares fall 1.1%.